AXC-715 trihydrochloride (Synonyms: T785 trihydrochloride) |
| Catalog No.GC65283 |
Le trichlorhydrate d'AXC-715 (T785) est un double agoniste TLR7/TLR8, extrait du brevet WO2020168017 A1.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2479276-17-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1[1]. AXC-715 trihydrochloride, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants[2].
[1]. Sung-Ju Moon, et al. Compositions containing, methods and uses of antibody-tlr agonist conjugates. Patent WO2020168017A1.
[2]. Shelley Erin ACKERMAN, et al. Immunoconjugates targeting pd-l1. Patent WO2020190734A1.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *